Effectiveness of Electroacupuncture and Electroconvulsive Therapy as Additional Treatment in Hospitalized Patients With Schizophrenia: A Retrospective Controlled Study

Jie Jia, Jun Shen, Feihu Liu, Hei Kiu Wong, Xinjing Yang, Qiangju Wu, Hui Zhang, Huaning Wang, Qihua Tan, Zhang‐Jin ZhangFrontiers in Psychology 2019 · DOI

Abstract

Electroacupuncture (EA) and electroconvulsive therapy (ECT) are often used in the management of schizophrenia. This study sought to determine whether additional EA and ECT could augment antipsychotic response and reduce related side effects. In this retrospective controlled study, 287 hospitalized schizophrenic patients who received antipsychotics (controls, n = 50) alone or combined with EA (n = 101), ECT (n = 55) or both (EA + ECT, n = 81) were identified. EA and ECT were conducted for 5 and 3 sessions per week, respectively, with a maximum of 12 sessions for ECT during hospitalization. The Scale for the Assessment of Positive Symptoms (SAPS) and Scale for the Assessment of Negative Symptoms (SANS) were used to assess the severity of psychotic symptoms. Clinical response on SAPS and SANS, weight gain, and adverse events were compared. Survival analysis revealed that the ECT and EA + ECT groups had markedly greater clinical response rate than controls on SAPS [72.7 and 90.1% vs. 64.0%; relative risk (RR), 1.974 and 2.628, respectively, P ≤ 0.004] and on SANS (67.3 and 70.4% vs. 42.0%; RR, 1.951 and 2.009, respectively, P ≤ 0.015). A significantly greater response rate on SANS than controls was also observed in the EA group (64.4% vs. 42.0%; RR = 1.938, P = 0.008). EA-containing regimens remarkably reduced weight gain and incidences of headache, insomnia, dry mouth, and electrocardiographic abnormalities. These results suggest that EA and ECT can serve as additional treatment for enhancing antipsychotic response and reduce the side effects in hospitalized patients with schizophrenia.

Introduction

While antipsychotic medications remain the cornerstone of schizophrenia treatment, they often fall short of achieving full remission and frequently cause significant side effects such as weight gain and metabolic dysfunction. Moreover, standard pharmacotherapy is typically more effective against "positive" symptoms (e.g., hallucinations) than "negative" symptoms (e.g., social withdrawal). This study, published in Frontiers in Psychology, investigates whether non-pharmacological neuromodulation—specifically electroacupuncture (EA) and electroconvulsive therapy (ECT)—can augment antipsychotic response and improve the safety profile for hospitalized patients.

Methods

This retrospective controlled study analyzed data from 287 hospitalized patients at the Xi’an Mental Health Center (2014–2018). Patients were divided into four treatment arms:

  1. Control (n=50): Standard antipsychotics only.
  2. EA + Meds (n=101): 5 sessions of EA per week (100 Hz, 20 min).
  3. ECT + Meds (n=55): 3 sessions of ECT per week (max 12 sessions).
  4. EA + ECT + Meds (n=81): Combination of both adjunct therapies.

Clinical response was defined as a reduction of 30% or more in SAPS (positive symptoms) or SANS (negative symptoms) scores.

Figure 1: Flowchart of patient screening and group allocation.

Key Results

The study found that adjunct neuromodulation significantly improved clinical outcomes across several domains:

Symptom Remission

Survival analysis demonstrated that the ECT and EA + ECT groups achieved significantly higher response rates for positive symptoms compared to the control group. Notably, all three adjunct groups (EA, ECT, and EA+ECT) showed superior performance in reducing negative symptoms, which are traditionally difficult to treat with medication alone.

Figure 2: Survival analysis of clinical response on positive (A) and negative (B) symptoms over 14 weeks.

Side Effect Mitigation

One of the most significant findings was the role of EA as a "metabolic buffer." Patients in the EA group gained significantly less weight (average 1.06 kg) compared to the control group (average 2.16 kg, P < 0.001). Furthermore, EA-containing regimens were associated with lower incidences of insomnia, dry mouth, and headaches.

Discussion and Conclusion

The results suggest that EA and ECT are effective adjuncts to standard antipsychotic therapy. The combination of EA and ECT yielded the highest response rate for positive symptoms (90.1%), indicating potential synergistic effects. Crucially, EA appears to mitigate common medication-induced side effects, potentially improving long-term treatment adherence.

While the retrospective nature and lack of blinding are limitations, the study highlights the promise of integrating traditional and modern neuromodulation techniques into psychiatric care. Future prospective, double-blind randomized controlled trials are needed to confirm these findings and elucidate the underlying biological mechanisms.

Summary updated

Abstract

Electroacupuncture (EA) and electroconvulsive therapy (ECT) are often used in the management of schizophrenia. This study sought to determine whether additional EA and ECT could augment antipsychotic response and reduce related side effects. In this retrospective controlled study, 287 hospitalized schizophrenic patients who received antipsychotics (controls, <i>n</i> = 50) alone or combined with EA (<i>n</i> = 101), ECT (<i>n</i> = 55) or both (EA + ECT, <i>n</i> = 81) were identified. EA and ECT were conducted for 5 and 3 sessions per week, respectively, with a maximum of 12 sessions for ECT during hospitalization. The Scale for the Assessment of Positive Symptoms (SAPS) and Scale for the Assessment of Negative Symptoms (SANS) were used to assess the severity of psychotic symptoms. Clinical response on SAPS and SANS, weight gain, and adverse events were compared. Survival analysis revealed that the ECT and EA + ECT groups had markedly greater clinical response rate than controls on SAPS [72.7 and 90.1% vs. 64.0%; relative risk (RR), 1.974 and 2.628, respectively, <i>P</i> ≤ 0.004] and on SANS (67.3 and 70.4% vs. 42.0%; RR, 1.951 and 2.009, respectively, <i>P</i> ≤ 0.015). A significantly greater response rate on SANS than controls was also observed in the EA group (64.4% vs. 42.0%; RR = 1.938, <i>P</i> = 0.008). EA-containing regimens remarkably reduced weight gain and incidences of headache, insomnia, dry mouth, and electrocardiographic abnormalities. These results suggest that EA and ECT can serve as additional treatment for enhancing antipsychotic response and reduce the side effects in hospitalized patients with schizophrenia. <b>Clinical Trial Registration:</b> http://www.chictr.org.cn/showprojen.aspx?proj=38901, identifier ChiCTR1900023563.
BibTeX
@inproceedings{jia2019effectiveness,
  author = {Jie Jia and Jun Shen and Feihu Liu and Hei Kiu Wong and Xinjing Yang and Qiangju Wu and Hui Zhang and Huaning Wang and Qihua Tan and Zhang‐Jin Zhang},
  title = {{Effectiveness of Electroacupuncture and Electroconvulsive Therapy as Additional Treatment in Hospitalized Patients With Schizophrenia: A Retrospective Controlled Study}},
  booktitle = {Frontiers in Psychology},
  year = {2019},
  doi = {10.3389/fpsyg.2019.02306},
}
Figure